phrykt

Beam Therapeutics Inc. (BEAM): who owns it and who trades it

As of Nov 16, 2026, BEAM insiders reported 31 open-market sales worth $19.7M and no purchases in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fmr Llc (10% owner), with $10M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Beam Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BEAM

277 funds and institutions reported BEAM shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 12.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)12.3%
Farallon Capital Management, L.l.c.9.9%
ARK Investment Management LLC9.9%
BlackRock, Inc.8.7%
State Street Corp5.7%
Vanguard Portfolio Management LLC4.8%
Vanguard Capital Management LLC4.5%
ARCH Venture Management, LLC4.4%
California State Teachers Retirement System3.5%
Amova Asset Management Americas, Inc.3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)12.61M12.26%$433M+1%
Farallon Capital Management, L.l.c.10.24M9.95%$351M+1%
ARK Investment Management LLC10.23M9.95%$351M-16%
BlackRock, Inc.9.00M8.75%$309M+6%
State Street Corp5.83M5.66%$200M+2%
Vanguard Portfolio Management LLC4.92M4.78%$169M+8%
Vanguard Capital Management LLC4.60M4.47%$158M+5%
ARCH Venture Management, LLC4.54M4.41%$156MNo change
California State Teachers Retirement System3.59M3.49%$105M+3229%
Amova Asset Management Americas, Inc.3.46M3.36%$119M-10%
Sumitomo Mitsui Trust Group, Inc.3.46M3.36%$119M-10%
T. Rowe Price Associates3.42M3.32%$117M+26%
Kynam Capital Management, LP2.84M2.76%$97.5M-23%
Geode Capital Management, LLC2.60M2.52%$89.1M+7%
Dimensional Fund Advisors LP2.23M2.16%$76.4M+3%
Morgan Stanley1.95M1.90%$67M+201%
Contrarius Group Holdings Ltd1.61M1.57%$55.4M+203%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.55M1.51%$53.3M-6%
Two Sigma Investments, LP1.39M1.35%$47.6M+15%
Casdin Capital, LLC1.35M1.31%$46.3MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BEAM insiders reported $0 of open-market purchases and $19.7M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$19.7M
31 trades, 7 people
Sales under a 10b5-1 plan
6%
Share of sale value
Latest trade
Oct 16, 2026
Filed Oct 16, 2026

Purchases and sales by month

$11.8M$11.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 16, 2026John M. EvansCEOSale plan25,000$23.98$600KForm 4
Oct 15, 2026John M. EvansCEOSale plan25,000$23.57$589KForm 4
Oct 1, 2026Bethany J CavanaghVice presidentSale plan187$24.41$4.6KForm 4
Jul 27, 2026Amy SimonChief Medical OfficerSale16,667$25.74$429KForm 4
Jun 30, 2026Amy SimonChief Medical OfficerSale373$34.73$13KForm 4
Jun 30, 2026John M. EvansCEOSale23,100$34.26$791KForm 4
Jun 30, 2026John M. EvansCEOSale1,900$34.84$66.2KForm 4
Jun 29, 2026John M. EvansCEOSale11,579$35.91$416KForm 4
Jun 29, 2026John M. EvansCEOSale13,421$35.13$471KForm 4
Jun 26, 2026Fmr Llc10% ownerSale251,488$35.26$8.9MForm 4
Jun 25, 2026Fmr Llc10% ownerSale33,372$35.12$1.2MForm 4
Apr 1, 2026John M. EvansCEOSale30,078$24.58$739KForm 4
Apr 1, 2026Amy SimonChief Medical OfficerSale6,700$24.58$165KForm 4
Apr 1, 2026Bethany J CavanaghVice presidentSale3,242$24.58$79.7KForm 4
Apr 1, 2026Christine BellonChief Legal OfficerSale5,956$24.58$146KForm 4
Apr 1, 2026Giuseppe CiaramellaPresidentSale11,810$24.58$290KForm 4
Mar 31, 2026John M. EvansCEOSale25,000$22.76$569KForm 4
Mar 30, 2026John M. EvansCEOSale25,000$22.37$559KForm 4
Feb 24, 2026Giuseppe CiaramellaPresidentSale35,000$32.00$1.1MForm 4
Jan 30, 2026John M. EvansCEOSale2,906$29.00$84.3KForm 4
Jan 30, 2026John M. EvansCEOSale22,094$28.27$625KForm 4
Jan 29, 2026John M. EvansCEOSale16,333$29.19$477KForm 4
Jan 29, 2026John M. EvansCEOSale8,667$29.74$258KForm 4
Jan 22, 2026Bethany J CavanaghVice presidentSale6,198$35.00$217KForm 4
Jan 22, 2026Christine BellonChief Legal OfficerSale1,371$34.00$46.6KForm 4
Jan 20, 2026Bethany J CavanaghVice presidentSale3,034$30.12$91.4KForm 4
Jan 15, 2026Christine BellonChief Legal OfficerSale15,959$34.72$554KForm 4
Jan 15, 2026Christine BellonChief Legal OfficerSale2,111$33.62$71KForm 4
Jan 15, 2026Christine BellonChief Legal OfficerSale559$35.40$19.8KForm 4
Dec 31, 2025Sravan Kumar EmanyCFOSale6,294$27.10$171KForm 4
Dec 31, 2025Christine BellonChief Legal OfficerSale1,254$27.10$34KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Fmr Llc10% owner–$10MJun 26, 2026
John M. EvansCEO, Director–$6.2MOct 16, 2026
Giuseppe CiaramellaPresident–$1.4MApr 1, 2026
Christine BellonChief Legal Officer–$872KApr 1, 2026
Amy SimonChief Medical Officer–$607KJul 27, 2026
Bethany J CavanaghSVP, Finance and Treasurer–$393KOct 1, 2026
Sravan Kumar EmanyChief Financial Officer–$171KDec 31, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BEAM short interest

Very high short interest. 25.2% of BEAM shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went down 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 26.08M BEAM shares were sold short, 25.2% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 13.7 trading days (days to cover).

Shares short, % of all shares

25.2%May 15Oct 3028.5%

Days to cover

13.7May 15Oct 3017.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202626.08M25.20%-1%1.90M13.7
Oct 15, 202626.24M25.41%-5%1.86M14.1
Sep 30, 202627.55M26.67%+6%1.80M15.3
Sep 15, 202625.88M25.06%+0%2.06M12.6
Aug 31, 202625.80M24.98%+6%1.74M14.8
Aug 14, 202624.37M23.60%+4%1.52M16.1
Jul 31, 202623.50M22.75%+1%2.08M11.3
Jul 15, 202623.22M22.57%+1%2.60M8.9
Jun 30, 202622.88M22.24%-19%2.73M8.4
Jun 15, 202628.31M27.52%+32%1.99M14.2
May 29, 202621.46M20.86%-19%1.83M11.7
May 15, 202626.52M25.77%+27%2.11M12.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Beam Therapeutics company events

Beam Therapeutics filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 8, 2026VoteReported shareholder vote results. Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Mar 5, 2026AgreementEnded an important agreement. Filing
  6. Feb 24, 2026AgreementBeam Therapeutics Inc. entered into a financing agreement with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto, and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. Filing
  7. Feb 12, 2026AgreementAs previously reported, Beam Therapeutics Inc. and Bio Palette Co., Ltd. are parties to a License Agreement dated March 27, 2019, pursuant to which the Company has sublicensed from Bio Palette certain patents that Bio Palette licensed directly from Kobe University under a License Agreement dated… Filing
  8. Feb 5, 2026LeadershipCarole Ho provided Beam Therapeutics Inc. with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing
  10. Dec 11, 2025DealBristol-Myers Squibb Company completed its previously announced acquisition of Orbital Therapeutics, Inc. pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Beam Therapeutics financials

Famous investors that hold BEAM

4 of the 50 well-known investors we track reported holding BEAM in their latest 13F filing. The largest position is Cathie Wood's, worth $289M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 202611.81M$289M1.7%+15%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026699,700$17.1M0.4%+356%
Paul Tudor Jones · Tudor Investment CorpQ3 202656,453$1.4M0.0%+15%
Israel Englander · Millennium ManagementQ3 202622,725$556K0.0%-34%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BEAM in the last 120 days.

FiledHolderFormStake
Nov 13, 2026ARK Investment Management LLC13G/A11.4%
Nov 13, 2026ARK Investment Management LLC13G/A11.4%

Questions about Beam Therapeutics Inc. (BEAM) stock

Who owns the most BEAM stock?

The largest reported owner of Beam Therapeutics Inc. (BEAM) is FMR LLC (Fidelity), with 12.3% of the company. In total, 277 funds and institutions reported holding BEAM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BEAM insiders buying or selling?

In the last 12 months, BEAM insiders reported no open-market purchases and 31 sales worth $19.7M. The latest trade was on Oct 16, 2026. See every trade.

What is the short interest in BEAM?

As of Oct 30, 2026, 26.08M BEAM shares were sold short, 25.2% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 13.7 trading days (days to cover). See the history.

Which famous investors hold BEAM?

4 of the 50 well-known investors we track reported BEAM in their latest 13F filing, including Cathie Wood, Stanley Druckenmiller, Paul Tudor Jones. The largest position is worth $289M. See all holders.

Executive pay

Beam Therapeutics's chief executive was paid a total of $5.8M for the year ended Dec 31, 2025, down 9% from $6.4M the year before. In the last 12 months, Beam Therapeutics's executives and directors bought no stock on the open market and sold $9.7M.

Chief executive, total pay$5.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$8.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.